Neuronetics Inc
NASDAQ:STIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (1.8), the stock would be worth $1.44 (15% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.2 | $1.69 |
0%
|
| 3-Year Average | 1.8 | $1.44 |
-15%
|
| 5-Year Average | 1.7 | $1.32 |
-22%
|
| Industry Average | 5.2 | $4.03 |
+139%
|
| Country Average | 6.5 | $5.09 |
+202%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Neuronetics Inc
NASDAQ:STIM
|
113.2m USD | 2.2 | -3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 23.4 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 6.3 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 8.1 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 5.2 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 6.6 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 8.9 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 16.7 | 41.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 5.1 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 5.7 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 9.1 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.2 |
| Median | 6.5 |
| 70th Percentile | 10.6 |
| Max | 1 764 211.7 |
Other Multiples
Neuronetics Inc
Glance View
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
